<DOC>
	<DOCNO>NCT01215279</DOCNO>
	<brief_summary>The purpose study investigate tolerability safety AZD2423 Patients chronic obstructive pulmonary disease .</brief_summary>
	<brief_title>AZD2423 Safety Tolerability Study Patients With Moderate Severe Chronic Obstructive Pulmonary Disease ( COPD )</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<criteria>Male female nonchild bear potential . Only woman nonchild bear potential include study i.e . woman permanently surgically sterilise post menopausal . Between 40 80 year age Visit 1 Clinical diagnosis COPD ( GOLD stage 2 3 ) FEV1/FVC &lt; 70 % FEV1 30 80 % predict normal postbronchodilator ( GOLD stage 2 3 ) Current exsmokers Any clinically significant disease disorder ( include history abnormal immune function ) , opinion Investigator , may either put subject risk influence way drug work Any lung disease COPD , recent respiratory infection resolve fully , active tuberculosis risk reactivation tuberculosis . Any abnormal finding physical examination , blood urine test result , vital sign ECG Visit 1 may put subject risk study , affect ability take part influence result study Immunisation live vaccine within 3 month vaccination within 30 day plan start treatment Worsening COPD symptom within 4 week prior start study need hospitalisation , oral steroid antibiotic .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Respiratory disease</keyword>
	<keyword>Chronic Obstructive Pulmonary Disease</keyword>
</DOC>